Is HPV Type 52 the Most Difficult to Treat—and Does It Affect Fertility or Pregnancy?

HPV type 52 is one of the high-risk human papillomavirus strains associated with cervical intraepithelial neoplasia and invasive cervical cancer. While it is not classified as “the most difficult to treat” among HPV genotypes, its clinical management presents unique challenges due to its relatively high oncogenic potential and frequent persistence—particularly in Asian populations, where prevalence rates are notably elevated. Unlike low-risk types (e.g., HPV 6 and 11), which cause benign warts and rarely progress, HPV 52 lacks a targeted antiviral therapy; treatment focuses on managing precancerous lesions (e.g., via loop electrosurgical excision procedure or cryotherapy) rather than eradicating the virus itself.

Importantly, HPV 52 infection does not impair fertility or reduce the likelihood of conception. There is no evidence that this genotype interferes with ovulation, tubal function, endometrial receptivity, or implantation. Women with persistent HPV 52 infection who have normal cervical cytology and colposcopy findings can pursue pregnancy safely. However, active high-grade squamous intraepithelial lesions (HSIL) may warrant evaluation and possible intervention prior to conception, depending on lesion size, location, and histologic grade—especially if there is concern for rapid progression during pregnancy-related immunomodulation.

Routine cervical cancer screening—including co-testing with cytology and HPV DNA testing—is essential for early detection of HPV 52–associated abnormalities. Vaccination with the 9-valent HPV vaccine (which covers HPV 52) remains the most effective preventive strategy, particularly when administered before sexual debut. For individuals already infected, immune clearance typically occurs within 12–24 months in immunocompetent women; persistent infection beyond this window warrants closer surveillance but does not contraindicate pregnancy planning.